Subsensitivity of striatal and mesolimbic dopamine target cells after repeated treatment with apomorphine dipivaloyl ester.
The effects of acute and repeated treatments with the dipivaloyl ester of apomorphine on behaviour and brain dopamine metabolism were compared in rats. A single injection of the ester (50 mg/kg i.p.) indued a stereotyped behaviour lasting for at least 6 h and a concomitant decrease in striatal HVA levels. After repeated treatment (twice daily for 7 days) with the drug, both the stereotyped behaviour and the decreases in striatal HVA levels were attenuated as compared to acute treatment; the minimal dose tested which induced this tolerance was found to be 25 mg/kg i.p. The minimal length of treatment with 50 mg/kg of the ester after which tolerance was observed was 3-4 days. The ED50 for haloperidol-induced catalepsy was about 4 times lower in rats treated with apomorphine dipivaloyl ester (50 mg/kg) for 7 days than in naive rats. Similarly, a shift to the left of the haloperidol dose-response curve for the increase in striatal dopamine metabolite levels was observed in rats treated subacutely with the ester as compared to control rats. Repeated treatment (7 days) with the dipivaloyl ester of apomorphine also attenuated the decrease in NVA levels seen with acute treatment in nucleus accumbens and tuberculum olfactorium; however, the threshold dose inducing tolerance in limbic regions was higher than in striatum. No difference in the brain concentrations of apomorphine was found after acute and repeated treatments with the ester. Thus, the present study provides evidence for the development of subsensitivity of dopamine receptors after repeated administration of aopomorphine dipivaloyl ester.
D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects*; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D008032:Limbic System / Q000166:cytology / Q000187:drug effects*; D008297:Male; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine; D006719:Homovanillic Acid